Publications by authors named "Christian M Kinstner"
The influence of diabetes mellitus (DM) on recurrent in-stent restenosis (ISR) of femoropopliteal arteries remains understudied. We investigated whether DM has an impact on recurrent restenosis after femoropopliteal stenting in patients included in the dRug-coatEd balloon angioPlasty for femoropopliteAl In-stent Restenosis (REPAIR) cooperation. The REPAIR cooperation pooled the patient-level data from 3 randomized trials in which patients with ISR of femoropopliteal arteries received either drug-coated balloon (DCB) or plain balloon angioplasty.
View Article and Find Full Text PDFDrug-Coated Balloon Angioplasty for Femoropopliteal In-Stent Restenosis.
Circ Cardiovasc Interv
December 2018
Article Synopsis
- The study evaluates the effectiveness of drug-coated balloon (DCB) angioplasty in treating in-stent restenosis (ISR) in femoropopliteal arteries compared to standard balloon angioplasty.
- Data from three randomized trials involving 263 patients showed that DCB angioplasty significantly reduced the risk of target lesion revascularization and recurrent ISR after one year.
- The results suggest DCB angioplasty offers better clinical outcomes than traditional methods, even in high-risk patients, but further research is needed to assess its long-term benefits.
Objectives: The hypothesis that paclitaxel-eluting balloon angioplasty provides higher 1-year patency rates in femoropopliteal artery in-stent restenosis compared with standard percutaneous transluminal angioplasty (PTA) was tested.
Background: Several trials have demonstrated that paclitaxel-eluting balloon angioplasty reduces late luminal loss in comparison with PTA.
Method: In a prospective, randomized, single-blind, dual-center study, 74 patients with symptomatic peripheral artery disease due to in-stent restenosis were treated with either paclitaxel-based drug-eluting balloon (DEB) angioplasty (n = 35) or standard PTA (n = 39).